Kocefan

Ceftriaxone, the active ingredient in Kocefan, is a third-generation cephalosporin presented as a injectable solution for intramuscular use. It treats serious bacterial infections such as community‑acquired pneumonia, meningitis, gonorrhea, urinary tract infections, and skin and soft‑tissue infections in adults and children as prescribed.

GNH USA supplies Kocefan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat bacterial infections affecting various organ systems.

- Community‑acquired pneumonia: provides rapid bacterial clearance leading to clinical recovery. - Meningitis: achieves high cerebrospinal fluid concentrations to eradicate the causative pathogens. - Gonorrhea: eliminates Neisseria gonorrhoeae, reducing symptoms and preventing complications. - Urinary tract infections: resolves infection by targeting common uropathogens. - Skin and soft‑tissue infections: eradicates susceptible bacteria, promoting wound healing.

Ceftriaxone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the intramuscular injection site. - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of queasiness without vomiting. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: rapid onset of life‑threatening allergic reaction. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hemolytic anemia: destruction of red blood cells leading to fatigue and pallor.

Ceftriaxone requires careful consideration of patient‑specific factors before use.

- Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Allergy history: avoid in patients with known cephalosporin or penicillin hypersensitivity. - Pregnancy and lactation: safety not established; weigh benefits versus risks. - Concomitant calcium‑containing solutions: do not mix in the same IV line due to precipitation risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone can interact with several medicines, necessitating monitoring or avoidance.

Major Interactions (Avoid): - Calcium‑containing IV solutions: may precipitate ceftriaxone, causing embolic events. - Warfarin: can enhance anticoagulant effect, increasing bleeding risk. - Neonates (≤28 days) receiving calcium‑containing fluids: risk of fatal precipitation.

Moderate Interactions (Monitor Closely): - Aminoglycosides: may increase nephrotoxicity when used together. - Loop diuretics: may heighten electrolyte disturbances. - Oral contraceptives: may reduce efficacy; advise additional contraceptive measures.